The UK Competition Authority welcomes the England & Wales Court of Appeal’s judgment, calling it an important step forward in clarifying the legal test for excessive and unfair pricing (Pfizer / Flynn Pharma)

KEYWORDS
References

UK Competition Authority, Pfizer / Flynn Pharma, Press release, 10 March 2020

England & Wales Court of Appeal, Pfizer / Flynn Pharma, [2020] EWCA Civ 339 Case No: C3/2018/1847 & 1874, 10 March 2020

CMA welcomes Court of Appeal judgment in Phenytoin case* The CMA welcomes today’s Court of Appeal judgment, calling it an important step forward in clarifying the legal test for excessive and unfair pricing. The Competition and Markets Authority (CMA) will now carefully review the elements that the court has decided to refer back to it, as it moves forward with its case against pharmaceutical companies Pfizer and Flynn Pharma. In December 2016, following a thorough investigation, the CMA

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • United Kingdom’s Competition Authority - CMA (London)
    United Kingdom 181 contributions 32301 visits

Quotation

UK Competition Authority, The UK Competition Authority welcomes the England & Wales Court of Appeal’s judgment, calling it an important step forward in clarifying the legal test for excessive and unfair pricing (Pfizer / Flynn Pharma), 10 March 2020, e-Competitions Judicial review, Art. N° 97329

Visites 55

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues